International Cancer Conference Journal最新文献

{"title":"Prophylactic use of duloxetine hydrochloride in oxaliplatin-induced first-bite syndrome.","authors":"Kensuke Uraguchi, Atsushi Muraoka, Shotaro Miyamoto, Munechika Tsumura","doi":"10.1007/s13691-024-00732-z","DOIUrl":"10.1007/s13691-024-00732-z","url":null,"abstract":"<p><p>First-bite syndrome (FBS) is manifested as acute and severe pain in the parotid region occurring at the first bite of a meal. While most cases of FBS arise after surgeries involving the deep lobe of the parotid gland, chemotherapy-induced FBS is extremely rare. Some adverse effects of oxaliplatin resemble FBS, suggesting it may be under-recognized. Here, we present a case of a 72 year-old male with oxaliplatin-induced FBS, effectively managed with the prophylactic administration of duloxetine hydrochloride. The patient, with a history of surgery for appendiceal adenocarcinoma, experienced sharp pain in the bilateral parotid regions at the beginning of each meal after the second to fourth courses of adjuvant chemotherapy with CapeOX (oxaliplatin and capecitabine). He was subsequently referred to our department for evaluation. Upon examination, no organic diseases were identified. Given the reproducible nature of the symptoms, oxaliplatin-induced FBS was diagnosed. We commenced prophylactic duloxetine hydrochloride before the fifth and sixth courses of chemotherapy, which significantly reduced the pain. After completing six courses of oxaliplatin, the patient no longer experienced symptoms of FBS, even without the continued administration of duloxetine hydrochloride. This case highlights that oxaliplatin can induce FBS, which can be effectively managed with duloxetine hydrochloride.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 1","pages":"35-38"},"PeriodicalIF":0.5,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11695535/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142931791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SMARCA4-deficient epithelioid sarcoma revealed by comprehensive genomic profiling, leading to a notable response by nivolumab treatment.","authors":"Mayumi Tokunaga, Hiroyuki Takahashi, Natsuki Hirose, Yuto Hibino, Hiroshi Teranaka, Kota Washimi, Yoichiro Okubo, Yukihiko Hiroshima, Masatsugu Tanaka, Rika Sakai","doi":"10.1007/s13691-024-00701-6","DOIUrl":"10.1007/s13691-024-00701-6","url":null,"abstract":"<p><p>A 50-year-old man presented with a bulky mass in the left thigh and was referred to our department. He showed an impaired Eastern Cooperative Oncology Group performance status of 3 due to swelling of the left thigh and pain. Imaging analysis revealed a large mass measuring 16 cm in the left thigh and right forearm, along with the bilateral adrenal gland, right lung, right axillary lymph nodes, liver, and left femur. Despite additional tests, including pathological examination, the primary origin of the tumors could not be identified. Because of the rapid tumor progression, he was placed on nivolumab (NIVO; 240 mg/body, every 2 weeks) monotherapy based on the diagnosis of cancer of unknown primary, unfavorable type. Simultaneous comprehensive genomic profiling (CGP) test revealed a high tumor mutation burden (15.69 Muts/Mb) and a truncating mutation of <i>SMARCA4</i>, along with loss of BRG1 expression detected by additional immunohistochemical (IHC) analysis. Based on the predominance of soft tissue in the lesion, histological and IHC findings, and genomic phenotype, the patient was finally re-diagnosed with SMARCA4-deficient, SMARCB1/INI-1-preserved epithelioid sarcoma (ES). He showed a dramatic improvement in physical and laboratory findings at 5 weeks after the initial NIVO dose. Although he experienced immune-related adverse events, such as liver dysfunction, colitis and relative adrenal failure, and severe sepsis due to pulmonary cyst infection, he was able to overcome these complications. By the 12th dose of NIVO (13 months after the initial treatment), he has exhibited a positive response to NIVO without any additional complications. Among SMARCA4-deficient tumors, there have been multiple reports on the sensitivity of SMARCA4-deficient thoracic tumors to immune checkpoint inhibitors (ICIs), including PD-1 blockade agents. This case indicates that SMARCA4-deficient SMARCB1/INI-1-preserved ES may share molecular pathological characteristics with SMARCA4-deficient thoracic tumors, given their similar sensitivity to ICIs. In addition, CGP may play an important role in hypothesizing the primary site of tumors and guiding treatment selection for rare cancers, as in the present case, which lacks established treatment options. Further data accumulation is essential to validate this approach.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 1","pages":"1-6"},"PeriodicalIF":0.5,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11695519/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142931809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reduction of bleeding by cabozantinib in metastatic renal cell carcinoma with hereditary hemorrhagic telangiectasia.","authors":"Satoshi Kitamura, Takuto Hara, Yasuyoshi Okamura, Tomoaki Terakawa, Koji Chiba, Jun Teishima, Yuzo Nakano, Hideaki Miyake","doi":"10.1007/s13691-024-00727-w","DOIUrl":"10.1007/s13691-024-00727-w","url":null,"abstract":"<p><p>Hereditary hemorrhagic telangiectasia (HHT) is a rare genetic disorder characterized by refractory recurrent epistaxis and gastrointestinal bleeding. Recent studies have reported the hemostatic effects of tyrosine kinase inhibitors on HHT-related bleeding. A 67-year-old man with HHT underwent laparoscopic radical nephrectomy for right renal cell carcinoma discovered during an investigation of anemia. Five years after surgery, pancreatic metastasis with biliary dilatation was found on computed tomography. After a biliary stent was inserted, the patient was treated with cabozantinib plus nivolumab. His hemoglobin level significantly improved from 4.8 g/dL to a maximum of 14.7 g/dL, and transfusion frequency reduced from five to one per 5 months. Despite tumor reduction after 6 months of treatment, the patient developed acute cholangitis because of biliary hemorrhage, which ultimately resulted in hepatic failure and death. This case is the first to indicate the potential of the tyrosine kinase inhibitor cabozantinib to control bleeding and tumor progression in patients with metastatic renal cell carcinoma with HHT-related bleeding.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 1","pages":"17-20"},"PeriodicalIF":0.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11695539/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142931808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HER2-targeted therapy is changing.","authors":"Noriomi Matsumura","doi":"10.1007/s13691-024-00730-1","DOIUrl":"https://doi.org/10.1007/s13691-024-00730-1","url":null,"abstract":"","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"13 4","pages":"325"},"PeriodicalIF":0.5,"publicationDate":"2024-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11464985/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142464409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiotherapy for cytokeratin-positive interstitial reticulum cell (CIRC) tumor on epicardium: a case report.","authors":"Masahide Anada, Haruyuki Fujita, Ryou Ishikawa, Shigeo Takahashi, Syunsuke Yoshida, Takamasa Nishide, Toshifumi Kinoshita, Norimitsu Kadowaki, Toru Shibata","doi":"10.1007/s13691-024-00729-8","DOIUrl":"10.1007/s13691-024-00729-8","url":null,"abstract":"<p><p>Cytokeratin-positive interstitial reticulum cell (CIRC) tumor is an extremely rare malignant neoplasm and a subtype of fibroblastic reticular cell tumor, classified within the dendritic cell tumor group. We describe a case of an epicardial CIRC tumor that was resected and subsequently recurred in the left pulmonary hilum. This recurrence was treated with immunotherapy followed by radiotherapy. A 71-year-old man with a history of colon cancer incidentally had a mass bordering the epicardium on a postoperative follow-up computed tomography scan. Pericardial tumor resection was performed due to suspected metastasis from colon cancer. Histopathologically, the patient was diagnosed as a CIRC tumor (programmed death ligand 1 expression rate > 95%). Seven months after pericardial surgery, the patient was treated with nivolumab because of local recurrence in the left pulmonary hilum, but the tumor size gradually increased. Three months after the initiation of nivolumab, the patient had a completely atelectatic left lung due to tumor invasion into the left main bronchus and was treated with external beam radiotherapy of 66 Gy in 33 fractions. One and a half months after the completion of radiotherapy, the atelectasis disappeared, and aeration was greatly improved. Three months after the completion of radiotherapy, atelectasis and pericardial effusion appeared owing to tumor regrowth, and the patient died of heart failure 2 months later. This report provides insights into the efficacy of immunotherapy and radiotherapy for CIRC tumor.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 1","pages":"27-34"},"PeriodicalIF":0.5,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11695555/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142931807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ponatinib and prednisolone induce sustained remission in a relapsed case of mixed-phenotype acute leukemia with <i>BCR::ABL1</i> fusion intolerant to dasatinib.","authors":"Hisaharu Shikata, Yuya Masuda, Kenichi Ishikawa, Masahiko Kaneko","doi":"10.1007/s13691-024-00725-y","DOIUrl":"10.1007/s13691-024-00725-y","url":null,"abstract":"<p><p>Mixed-phenotype acute leukemia (MPAL) with <i>BCR::ABL1</i> fusion is a rare leukemia subtype exhibiting both myeloid and lymphoid traits. Standard treatment involves chemotherapy with a tyrosine kinase inhibitor (TKI). However, establishing the optimal treatment strategy for elderly patients with MPAL with <i>BCR::ABL1</i> fusion is challenging due to their intolerance to intensive chemotherapy. It has not yet been determined whether therapy with a TKI and prednisolone, a combination known to be effective in elderly patients with B-lymphoblastic leukemia with <i>BCR::ABL1</i> fusion is also safe and effective for MPAL with <i>BCR::ABL1</i> fusion. Here we report the first example of an elderly patient with MPAL with <i>BCR::ABL1</i> fusion who was treated successfully with ponatinib and prednisolone. Despite achieving complete response with dasatinib plus chemotherapy, the patient suffered a relapse during the withdrawal of dasatinib and had two episodes of gastrointestinal bleeding attributed to the dasatinib therapy, necessitating therapy discontinuation. The treatment was then switched to a regimen of ponatinib and prednisolone, and the patient achieved and maintained complete molecular remission for over seven years without any serious adverse events. This case suggests that ponatinib, with or without prednisolone, could be a potential salvage option for elderly patients with MPAL with <i>BCR::ABL1</i> fusion who suffer relapse or are intolerant to dasatinib.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 1","pages":"7-11"},"PeriodicalIF":0.5,"publicationDate":"2024-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11695517/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142931790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case of gastritis caused by immune checkpoint inhibitor treated with infliximab.","authors":"Shizu Itsukage, Noriko Kume, Aki Tajima, Takashi Okazaki, Koji Tsuta, Hideaki Tanizaki","doi":"10.1007/s13691-024-00709-y","DOIUrl":"10.1007/s13691-024-00709-y","url":null,"abstract":"<p><p>Immune checkpoint inhibitors (ICIs) can cause immune-related adverse events (irAEs) in various organs. Herein, we present a rare case involving a patient with immunotherapy-related gastritis who developed refractory vomiting and anorexia after treatment with nivolumab for cutaneous malignant melanoma. The patient was treated with oral corticosteroids, but the efficacy was limited. The symptoms improved markedly after treatment with infliximab. With the increasing use of ICIs, the number of reports of gastritis due to irAEs has also increased. Health care providers treating malignancies should be aware of this side effect and know how to diagnose and treat it.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"13 4","pages":"454-459"},"PeriodicalIF":0.5,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11464928/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142464373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intraventricular ganglioneuroblastoma: an uncommon location for a rare tumour in a young adult with review of literature.","authors":"Tarang Patel, Garima M Anandani, Virendrakumar Meena","doi":"10.1007/s13691-024-00726-x","DOIUrl":"10.1007/s13691-024-00726-x","url":null,"abstract":"<p><p>Ganglioneuroblastoma (GNB) is a rare tumour of neuroectodermal origin consisting of a varying proportion of neuroblasts and ganglion cells. GNB arises from sympathoadrenal tissue usually affecting young children. Very few cases of brain GNB have been reported in the literature. To the best of our knowledge, this is the first-ever reported case of GNB at an intraventricular location in young adults. Because of the rarity of the neoplasm, it might be confused with other tumours of intraventricular location both in radiology and histopathology. We report a very rare case, which was surgically operated on and sent for a frozen section followed by a routine report. The final diagnosis was made by Immunohistochemistry (IHC) study. The patient was treated with further radiotherapy.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 1","pages":"12-16"},"PeriodicalIF":0.5,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11695542/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142931784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SMARCA4-deficient uterine tumors in young women: response to immune checkpoint inhibitors.","authors":"Riku Suzui, Mana Taki, Sachiko Kitamura, Masumi Sunada, Koji Yamanoi, Ryusuke Murakami, Ken Yamaguchi, Junzo Hamanishi, Sachiko Minamiguchi, Masaki Mandai","doi":"10.1007/s13691-024-00721-2","DOIUrl":"10.1007/s13691-024-00721-2","url":null,"abstract":"<p><p>SMARCA4-deficient tumors have been reported in various organs and are associated with a poor prognosis. SMARCA4-deficient undifferentiated uterine sarcoma (SDUS) was first described in 2018. Conversely, loss of SMARCA4 (BRG1) expression, as observed by immunostaining, has been observed in several cases of undifferentiated endometrial carcinoma. SDUS has considerable morphologic overlap with undifferentiated endometrial carcinoma, while there are differences in their clinicopathological features. Here, we present two cases of SMARCA4-deficient uterine tumors in patients in their 20 s: SDUS (<i>Case 1</i>) and undifferentiated endometrial carcinoma without SMARCA4 nuclear expression (<i>Case 2</i>). Using comprehensive genome profiling, we found that both cases had <i>SMARCA4</i> mutations, with tumor mutation burdens of 0 and 68 Muts/Mb, respectively. <i>Case 1</i> had multiple lung metastases 9 months after surgery. We treated the patients with combination of an immune checkpoint inhibitor (pembrolizumab) and a multikinase inhibitor (lenvatinib), and the response to the treatment was stable. This study presents the first report on the response to immune checkpoint inhibitor and multikinase inhibitor in SDUS.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s13691-024-00721-2.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"13 4","pages":"515-519"},"PeriodicalIF":0.5,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11465112/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142464420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case of grade1 follicular lymphoma diagnosed by laparoscopic lymph node resection: differentiating from late lymph node recurrence of endometrial cancer.","authors":"Shingo Koyama, Haruko Okamoto, Koji Yamanoi, Rin Mizuno, Masumi Sunada, Mana Taki, Ryusuke Murakami, Hiroaki Ito, Ken Yamaguchi, Junzo Hamanishi, Masaki Mandai","doi":"10.1007/s13691-024-00724-z","DOIUrl":"10.1007/s13691-024-00724-z","url":null,"abstract":"<p><p>Follicular lymphoma is a common hematologic malignancy; however, it is less common among all malignant diseases and is difficult to suspect in advance due to the lack of specific clinical findings. Here, we report a case in which a late recurrence of corpus cancer was first suspected and finally diagnosed as follicular lymphoma. A 67-year-old female presented to our department with enlarged pelvic lymph nodes. She was diagnosed with breast cancer (HER2-posiotive with lymph node metastasis) and corpus cancer (endometrioid carcinoma grade 2, stage IA) 16 years prior, received definitive therapy and was followed up. A positron emission tomography scan was performed, and an accumulation of 18F-fluorodeoxyglucose (FDG) was detected in multiple lymph nodes, including the lymph nodes with no change in size or enlargement. We performed laparoscopic resection of the enlarged and FDG-accumulated lymph nodes and a pathological examination. The patient was diagnosed with follicular lymphoma (FL) grade 1 and is currently under observation at the Department of Hematology. FL can be considered when there is a discrepancy between the change in lymph node size and the degree of FDG accumulation. A pathological examination is useful for accurate diagnosis. Therefore, it is important to consider tissue collection; however, care must be taken to minimize the invasiveness of the procedure for the patient.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"13 4","pages":"525-531"},"PeriodicalIF":0.5,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11465014/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142464374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}